Clinical trial

Cadonilimab Monotherapy as Neoadjuvant Therapy for Resectable II-IIIA Squamous Cell Lung Cancer

NCT05784974

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2023-05-01

PhasePHASE2

Study timeline

Study start (estimated)2023-05-01Date precision: day

Registry last updated2023-03-27

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Lung Cancerunresolved

Interventions

CadonilimabDRUG

Sponsors & collaborators

The First Hospital of Jilin Universitylead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05784974 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.